Step 1: Begin with the pathophysiology of menopause - ovarian estrogen production declines, producing the hypoestrogenic symptom complex. HT aims to correct this deficiency.
Step 2: The best-established benefit of replacing estrogen is suppression of vasomotor instability. Hot flashes are the hallmark vasomotor symptom and respond strongly to HT, which is why this is its core licensed use (alongside osteoporosis prophylaxis).
Step 3: Matching the option, hot flash is the indicated condition.
Step 4: The other options are excluded on safety grounds: breast cancer is estrogen-sensitive so HT is contraindicated, endometriosis worsens under estrogen, and unexplained uterine bleeding demands evaluation for malignancy before any hormone is given.
\[\boxed{\text{Hot flash}}\]